Prescribing information
... LAMISIL Oral Granules are contraindicated for patients with chronic or active liver disease. Before prescribing LAMISIL Oral Granules, perform liver function tests because hepatotoxicity may occur in patients with and without preexisting liver disease. Cases of liver failure, some leading to liver t ...
... LAMISIL Oral Granules are contraindicated for patients with chronic or active liver disease. Before prescribing LAMISIL Oral Granules, perform liver function tests because hepatotoxicity may occur in patients with and without preexisting liver disease. Cases of liver failure, some leading to liver t ...
ALDACTAZIDE
... hepatic function, because minor alterations in electrolyte balance may precipitate hepatic coma. In the treatment of the edema/ascites of cirrhosis, when high doses of ALDACTAZIDE are required, it is recommended that the drug dosage be decreased before diuresis is complete, in order to avoid dehydra ...
... hepatic function, because minor alterations in electrolyte balance may precipitate hepatic coma. In the treatment of the edema/ascites of cirrhosis, when high doses of ALDACTAZIDE are required, it is recommended that the drug dosage be decreased before diuresis is complete, in order to avoid dehydra ...
AusPAR: Pitavastatin - Therapeutic Goods Administration
... tablets1. These strengths contain cores in direct scale and given that the pharmacokinetics are linear from 1-8 mg can be considered bioequivalent (that is, 1 x 4 mg, 2 x 2 mg and 4 x 1 mg will all give the same response). The 1 mg, 2 mg and 4 mg tablets proposed for marketing are identical to those ...
... tablets1. These strengths contain cores in direct scale and given that the pharmacokinetics are linear from 1-8 mg can be considered bioequivalent (that is, 1 x 4 mg, 2 x 2 mg and 4 x 1 mg will all give the same response). The 1 mg, 2 mg and 4 mg tablets proposed for marketing are identical to those ...
CYP2D6 - PGXL Laboratories
... CYP2C9 Poor Metabolizer (PM): This patient’s genotype is consistent with significantly reduced CYP2C9 enzymatic activity. Reduced CYP2C9 activity leads to lower dose requirement (e.g., warfarin) due to decreased clearance, increased elimination half-life, and increased time to reach steady-state blo ...
... CYP2C9 Poor Metabolizer (PM): This patient’s genotype is consistent with significantly reduced CYP2C9 enzymatic activity. Reduced CYP2C9 activity leads to lower dose requirement (e.g., warfarin) due to decreased clearance, increased elimination half-life, and increased time to reach steady-state blo ...
view/Open[285279] - S
... lopidogrel is an antiplatelet drug widely used in the management of coronary artery disease. 1 It decreases the incidence of coronary artery stent thrombosis2,3 and has been approved for the management of nonST-segment elevation myocardial infarction.4 Recent reports have indicated a lack of platele ...
... lopidogrel is an antiplatelet drug widely used in the management of coronary artery disease. 1 It decreases the incidence of coronary artery stent thrombosis2,3 and has been approved for the management of nonST-segment elevation myocardial infarction.4 Recent reports have indicated a lack of platele ...
Ketorolac Tromethamine Injection, USP
... The mean apparent volume (Vß) of ketorolac tromethamine following complete distribution was approximately 13 liters. This parameter was determined from single-dose data. The ketorolac tromethamine racemate has been shown to be highly protein bound (99%). Nevertheless, plasma concentrations as high a ...
... The mean apparent volume (Vß) of ketorolac tromethamine following complete distribution was approximately 13 liters. This parameter was determined from single-dose data. The ketorolac tromethamine racemate has been shown to be highly protein bound (99%). Nevertheless, plasma concentrations as high a ...
Antimicrobial Dosing for Adults in Renal Impairment
... (round dose to nearest 200mg) maintenance dose 6mg/kg once daily. Bone and joint infection/endocarditis: Loading dose 12mg/kg maintenance dose (max 800mg) Give post HD (round dose to nearest 200mg) (no maximum dose) every 12 hours for 3 doses then maintenance dose 12mg/kg once daily. (Maximum starti ...
... (round dose to nearest 200mg) maintenance dose 6mg/kg once daily. Bone and joint infection/endocarditis: Loading dose 12mg/kg maintenance dose (max 800mg) Give post HD (round dose to nearest 200mg) (no maximum dose) every 12 hours for 3 doses then maintenance dose 12mg/kg once daily. (Maximum starti ...
WARNINGS - Boehringer Ingelheim
... the recommended dosage ranges, the clearance of the racemate does not change. This implies that the pharmacokinetics of ketorolac tromethamine in adults, following single or multiple IM, IV or recommended oral doses of ketorolac tromethamine, are linear. At the higher recommended doses, there is a p ...
... the recommended dosage ranges, the clearance of the racemate does not change. This implies that the pharmacokinetics of ketorolac tromethamine in adults, following single or multiple IM, IV or recommended oral doses of ketorolac tromethamine, are linear. At the higher recommended doses, there is a p ...
Dosage Adjustment for Cytotoxics in Renal Impairment
... SPC (Mayne pharma) – If creatinine 177-354μmol/L, give 50% dose. If creatinine >354μmol/L, further reduction is necessary. The rate of excretion is highly influenced by renal function; concentrations in plasma are greatly elevated if usual doses are given to patients with renal impairment with only ...
... SPC (Mayne pharma) – If creatinine 177-354μmol/L, give 50% dose. If creatinine >354μmol/L, further reduction is necessary. The rate of excretion is highly influenced by renal function; concentrations in plasma are greatly elevated if usual doses are given to patients with renal impairment with only ...
Dosage Adjustment for Cytotoxics in Renal Impairment
... SPC (Mayne pharma) – If creatinine 177-354mol/L, give 50% dose. If creatinine >354mol/L, further reduction is necessary. The rate of excretion is highly influenced by renal function; concentrations in plasma are greatly elevated if usual doses are given to patients with renal impairment with only ...
... SPC (Mayne pharma) – If creatinine 177-354mol/L, give 50% dose. If creatinine >354mol/L, further reduction is necessary. The rate of excretion is highly influenced by renal function; concentrations in plasma are greatly elevated if usual doses are given to patients with renal impairment with only ...
Dosage Adjustment for Cytotoxics in Renal Impairment
... SPC (Mayne pharma) – If creatinine 177-354mol/L, give 50% dose. If creatinine >354mol/L, further reduction is necessary. The rate of excretion is highly influenced by renal function; concentrations in plasma are greatly elevated if usual doses are given to patients with renal impairment with only ...
... SPC (Mayne pharma) – If creatinine 177-354mol/L, give 50% dose. If creatinine >354mol/L, further reduction is necessary. The rate of excretion is highly influenced by renal function; concentrations in plasma are greatly elevated if usual doses are given to patients with renal impairment with only ...
BIOAVAILABILITY OF ORAL PROPOFOL IN HUMANS Victor
... 80%,2,3 and thus the expected bioavailability of orally administered should not exceed 20%. Raoof and colleagues found that gut microsomal preparations had similar propofol metabolic capacity to liver microsomal preparations. The combined first-pass effects of gut metabolism and hepatic metabolism l ...
... 80%,2,3 and thus the expected bioavailability of orally administered should not exceed 20%. Raoof and colleagues found that gut microsomal preparations had similar propofol metabolic capacity to liver microsomal preparations. The combined first-pass effects of gut metabolism and hepatic metabolism l ...
Product Information - Therapeutic Goods Administration
... integrase substitutions T66I, E92Q, and Q148R. Additional integrase substitutions observed in cell culture selection included H51Y, F121Y, S147G, S153Y, E157Q, and R263K. Elvitegravir showed cross-resistance in vitro to the raltegravir selected mutations T66A/K, Q148H/K, and N155H. Cobicistat: No in ...
... integrase substitutions T66I, E92Q, and Q148R. Additional integrase substitutions observed in cell culture selection included H51Y, F121Y, S147G, S153Y, E157Q, and R263K. Elvitegravir showed cross-resistance in vitro to the raltegravir selected mutations T66A/K, Q148H/K, and N155H. Cobicistat: No in ...
Clinical Pharmacology of Boceprevir (BOC): Metabolism
... Protease inhibitor of the ketoamide class Binds reversibly to active site of HCV NS3 protease to inhibit HCV replication (IC90 400 nM) o Phase 3 trials in treatment-naive and treatmentexperienced genotype 1 HCV patients complete o o ...
... Protease inhibitor of the ketoamide class Binds reversibly to active site of HCV NS3 protease to inhibit HCV replication (IC90 400 nM) o Phase 3 trials in treatment-naive and treatmentexperienced genotype 1 HCV patients complete o o ...
Atrial fibrillation: management
... concurrent medication, for example concomitant use of aspirin or a non-steroidal anti-inflammatory drug (NSAID) harmful alcohol consumption. [new 2014] ...
... concurrent medication, for example concomitant use of aspirin or a non-steroidal anti-inflammatory drug (NSAID) harmful alcohol consumption. [new 2014] ...
DMSO inhibits human platelet activation through cyclooxygenase
... The exogenous thromboxane A2 analogue U46619 prevented the inhibitory effect of DMSO on platelet aggregation implying that DMSO alters the release of prothrombotic thromboxane A2. Thromboxane A2 is a potent platelet activating eicosanoid synthesised from COX-dependent endoperoxides [2] and its inhib ...
... The exogenous thromboxane A2 analogue U46619 prevented the inhibitory effect of DMSO on platelet aggregation implying that DMSO alters the release of prothrombotic thromboxane A2. Thromboxane A2 is a potent platelet activating eicosanoid synthesised from COX-dependent endoperoxides [2] and its inhib ...
PRODUCT MONOGRAPH PrLUVOX
... combination with other serotonergic and / or neuroleptic/antipsychotic drugs. As these syndromes may result in potentially life-threatening conditions, treatment with LUVOX® should be discontinued if patients develop a combination of symptoms possibly including hyperthermia, rigidity, myoclonus, aut ...
... combination with other serotonergic and / or neuroleptic/antipsychotic drugs. As these syndromes may result in potentially life-threatening conditions, treatment with LUVOX® should be discontinued if patients develop a combination of symptoms possibly including hyperthermia, rigidity, myoclonus, aut ...
HYDROCODONE BITARTRATE AND ACETAMINOPHEN ORAL
... sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be ca ...
... sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be ca ...
DIPYRIDAMOLE TABLETS USP 25 MG, 50 MG AND 75 MG
... In three randomized controlled clinical trials involving 854 patients who had undergone surgical placement of a prosthetic heart valve, dipyridamole tablets, in combination with warfarin, decreased the incidence of postoperative thromboembolic events by 62 to 91% compared to warfarin treatment alone ...
... In three randomized controlled clinical trials involving 854 patients who had undergone surgical placement of a prosthetic heart valve, dipyridamole tablets, in combination with warfarin, decreased the incidence of postoperative thromboembolic events by 62 to 91% compared to warfarin treatment alone ...
Candesartan Aspen
... Candesartan cilexetil is a prodrug suitable for oral use. It is rapidly converted to the active drug, candesartan, by ester hydrolysis during absorption from the gastrointestinal tract. Candesartan is an angiotensin II receptor antagonist, selective for AT 1 receptors, with tight binding to and slo ...
... Candesartan cilexetil is a prodrug suitable for oral use. It is rapidly converted to the active drug, candesartan, by ester hydrolysis during absorption from the gastrointestinal tract. Candesartan is an angiotensin II receptor antagonist, selective for AT 1 receptors, with tight binding to and slo ...
REVIEW ON CONVENTIONAL AND NOVEL TECHNIQUES FOR TREATMENT OF ALVEOLAR OSTEITIS
... The incidence of oral infections is increased to a large extent in recent years. Alveolar osteitis (AO) commonly known as Dry Socket is one such commonly occurring complication on mandibular tooth extraction. Alveolar osteitis is mainly associated with postoperative pain inside and around the extrac ...
... The incidence of oral infections is increased to a large extent in recent years. Alveolar osteitis (AO) commonly known as Dry Socket is one such commonly occurring complication on mandibular tooth extraction. Alveolar osteitis is mainly associated with postoperative pain inside and around the extrac ...
T Th he eo
... mg daily) in children with mild to moderate asthma [14]. This suggests that theophylline may be used in combination with inhaled steroids to control asthma, without the need to increase the dose of inhaled steroids when symptoms are not controlled at doses of 0.4–0.8 mg daily. Controlled trials are ...
... mg daily) in children with mild to moderate asthma [14]. This suggests that theophylline may be used in combination with inhaled steroids to control asthma, without the need to increase the dose of inhaled steroids when symptoms are not controlled at doses of 0.4–0.8 mg daily. Controlled trials are ...
- Boehringer Ingelheim (Canada)
... PCP, and TB), which may necessitate further evaluation and treatment. Autoimmune disorders (such as Graves´ disease, polymyositis and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable and can occur many mont ...
... PCP, and TB), which may necessitate further evaluation and treatment. Autoimmune disorders (such as Graves´ disease, polymyositis and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable and can occur many mont ...
Renal Analgesic Brochure
... extreme caution is necessary and a higher ratio may be required when switching from high doses of other opioids. Available: powder – compounded as 1 mg/mL oral liquid; as well as 10, 15 and 25 mg/tablet. ...
... extreme caution is necessary and a higher ratio may be required when switching from high doses of other opioids. Available: powder – compounded as 1 mg/mL oral liquid; as well as 10, 15 and 25 mg/tablet. ...
Discovery and development of direct thrombin inhibitors
Direct thrombin inhibitors (DTIs) are a class of anticoagulant drugs that can be used to prevent and treat embolisms and blood clots caused by various diseases. They inhibit thrombin, a serine protease which affects the coagulation cascade in many ways. DTIs have undergone rapid development since the 90's. With technological advances in genetic engineering the production of recombinant hirudin was made possible which opened the door to this new group of drugs. Before the use of DTIs the therapy and prophylaxis for anticoagulation had stayed the same for over 50 years with the use of heparin derivatives and warfarin which have some well known disadvantages. DTIs are still under development, but the research focus has shifted towards factor Xa inhibitors, or even dual thrombin and fXa inhibitors that have a broader mechanism of action by both inhibiting factor IIa (thrombin) and Xa. A recent review of patents and literature on thrombin inhibitors has demonstrated that the development of allosteric and multi-mechanism inhibitors might lead the way to a more safer anticoagulant.